Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Fineline Cube Jul 1, 2026
Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Fineline Cube Jul 1, 2026
Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting

Fineline Cube Jul 1, 2026
Company Drug

Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease – ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks

Fineline Cube Jul 1, 2026
Company Deals

Burning Rock Partners with AstraZeneca to Develop Companion Diagnostics for Cancer Therapies

Fineline Cube Aug 9, 2023

Guangzhou-based medical device giant Burning Rock (NASDAQ: BNR) has announced a strategic partnership with AstraZeneca...

Company Policy / Regulatory

Audit Reveals Illicit Payments and Inflated Prices in Pharmaceutical Industry

Fineline Cube Aug 9, 2023

An audit has shed light on the use of third-party business promotion companies as a...

Company

Eli Lilly & Co. Reports 28% YOY Revenue Increase in Q2 2023 Financials

Fineline Cube Aug 9, 2023

US pharmaceutical giant Eli Lilly & Co., (NYSE: LLY) has released its financial results for...

Company

FibroGen’s Evrenzo Achieves Record Sales in China, Outlook for 2024 Remains Promising

Fineline Cube Aug 9, 2023

US-based biopharmaceutical company FibroGen Inc., (NASDAQ: FGEN) has released its financial report for the second...

Company

Bayer AG Reports Q2/H1 2023 Financials with Challenges in Crop Science and Pharmaceuticals

Fineline Cube Aug 9, 2023

Germany-based multinational Bayer AG (ETR: BAYN) has released its financial report for the second quarter...

Company Drug

Novo Nordisk’s Wegovy Demonstrates 20% Reduction in Cardiovascular Events in SELECT Trial

Fineline Cube Aug 9, 2023

Denmark-based pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) has released topline data supporting the use...

Policy / Regulatory

Shanghai Health Commission Issues Regulations to Curb Unhealthy Pharmaceutical Practices

Fineline Cube Aug 9, 2023

In alignment with the No. 75 Document by the National Health Commission, the Shanghai...

Company Deals

CanSino Biotechnology Partners with AstraZeneca for mRNA Vaccine Development and Manufacturing

Fineline Cube Aug 9, 2023

China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has announced a product supply cooperation framework...

Company Drug

Lynk Pharmaceuticals’ LNK01001 Shows Positive Results in Atopic Dermatitis Phase II Study

Fineline Cube Aug 9, 2023

China-based Lynk Pharmaceuticals Co., Ltd has announced that its Phase II clinical study for LNK01001...

Company Deals

BioNTech Expands Partnership with Duality Biologics for Global Rights to ADC DB-1305

Fineline Cube Aug 8, 2023

Germany-based BioNTech SE (NASDAQ: BNTC) has entered into a cooperation expansion agreement with its existing...

Company Legal / IP

Johnson & Johnson Reaches Settlement with Fresenius Kabi and Formycon AG for Stelara Biosimilar

Fineline Cube Aug 8, 2023

US pharmaceutical giant Johnson & Johnson (J&J; NYSE: JNJ) has entered into its latest settlement...

Company Drug

VistaGen’s Fasedienol Phase III Success Sends Shares Soaring Over 600%

Fineline Cube Aug 8, 2023

Shares of San Francisco-based biotech VistaGen (NASDAQ: VTGN) experienced a dramatic increase of over 600%...

Company Legal / IP

Nektar Therapeutics and Eli Lilly & Co. Face Off in Court Over REZPEG Partnership Dispute

Fineline Cube Aug 8, 2023

A legal feud between US-based Nektar Therapeutics (NASDAQ: NKTR) and pharmaceutical giant Eli Lilly &...

Company Drug

BioCity Biopharma Receives FDA IND Approval for CD3-EGFR BsAb BC3448

Fineline Cube Aug 8, 2023

China-based biotechnology company BioCity Biopharma has announced that it has received Investigational New Drug (IND)...

Company

Zai Lab Ltd Reports Q2 2023 Financials with 53% YOY Product Revenue Growth

Fineline Cube Aug 8, 2023

China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has released its financial results for the...

Company Deals

Beijing’s Gene Cradle Secures Pre-Series B+ Funding Led by Cash Capital

Fineline Cube Aug 8, 2023

Gene Cradle, a Beijing-based gene therapy specialist, has reportedly secured tens of millions of renminbi...

Company Deals

Gracell Biotechnologies Secures $100 Million in Private Placement with Healthcare Investors

Fineline Cube Aug 8, 2023

Suzhou-based biotech firm Gracell Biotechnologies Inc., (NASDAQ: GRCL) has announced a purchase agreement with a...

Policy / Regulatory

National Health Commission Unveils 10 Measures to Enhance Primary Healthcare Services

Fineline Cube Aug 8, 2023

The National Health Commission has issued a Notice outlining “Measures for Grassroots Health and Convenient...

Company Drug

Biogen and Sage Therapeutics Receive FDA Approval for Postpartum Depression Treatment Zurzuvae

Fineline Cube Aug 7, 2023

Biogen Inc., (NASDAQ: BIIB) and its partner Sage Therapeutics Inc., (NASDAQ: SAGE) have announced that...

Company Deals

ABVC Biopharma Grants Xinnovation Therapeutics Exclusive Rights to CNS Drug Pipeline in China

Fineline Cube Aug 7, 2023

US-based ABVC Biopharma Inc. has entered into a legally binding term sheet with China-based Xinnovation...

Posts pagination

1 … 514 515 516 … 689

Recent updates

  • RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development
  • CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting
  • Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease – ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks
  • BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study – Chemotherapy-Free Regimen Shows Significant PFS Benefit
  • Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Company Drug

CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting

Company Drug

Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease – ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks

Company Drug

BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study – Chemotherapy-Free Regimen Shows Significant PFS Benefit

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.